Q4 2014 · —
Revenue$328.14M$328.14M +39.2% vs Q4 2013+7.0% vs Q3 2014
Net Income$81.61M$81.61M +47.6% vs Q4 2013+216.7% vs Q3 2014
EPS Diluted$1.30$1.30 +44.4% vs Q4 2013+217.1% vs Q3 2014
Gross Profit$295,415,000+41.9%
Operating Incomederived$129,919,000+37.5%
Operating Cash Flowderived$134,262,000+69.9%
Free Cash Flowderived$120,714,000+59.0%
Margins · derived
Gross margin90.0%+1.7 pt vs Q4 2013
Operating margin39.6%−0.5 pt vs Q4 2013
Net margin24.9%+1.4 pt vs Q4 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q4 2014 | Q4 2013 | Q4 2012 | Q4 2011 |
|---|---|---|---|---|
| Revenue | $328.14M | $235.77M | $183.70M | $83.54M |
| Net Income | $81.61M | $55.29M | $200.55M | $37.47M |
| EPS Diluted | $1.30 | $0.90 | $3.28 | $0.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR